Regencell Bioscience Holdings Limited
7.67USD
-2.1400 (-21.81%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on RGC.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| FY | — | — | — | — | — |
| Q1 | — | — | — | — | — |
| Q2 | — | — | — | — | — |
| Q3 | — | — | — | — | — |
| Q4 | — | — | — | — | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| FY | -.015 | -.012 | -.009 | -.007 | — |
| Q1 | — | — | — | — | — |
| Q2 | — | — | — | — | — |
| Q3 | — | — | — | — | — |
| Q4 | — | — | — | — | — |
Fiscal period: Reported, Estimated. Reported figures: Yahoo Finance (limited history). No forward consensus is cached for this security yet. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
Debt level and coverage